Why the study?
Severe fever with thrombocytopenia syndrome has an increasing prevalence and an approximately 10% case fatality rate, but its underlying pathogenic mechanisms remain poorly understood, limiting therapeutic development.
Can metabolic biomarkers predict disease severity and clinical outcomes in patients with SFTS?
Population
78 SFTS patients during the acute phase of illness
Comparison
Survival vs fatal cases
Authors
Loading...
Elevated phenyllactic and isocitric acid may aid early SFTS risk stratification; leaves open prospective validation before clinical adoption.
Can metabolic biomarkers predict disease severity and clinical outcomes in patients with SFTS?
Metabolic profiling identified phenyllactic acid and isocitric acid as potential prognostic biomarkers for predicting disease severity in SFTS patients.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: